Clinical Trials Logo

Arteritis clinical trials

View clinical trials related to Arteritis.

Filter by:

NCT ID: NCT00556439 Completed - Clinical trials for Giant Cell Arteritis

Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis

Start date: December 2008
Phase: Phase 2
Study type: Interventional

Giant cell arteritis (GCA) and Takayasu's arteritis (TAK) are diseases that cause swelling of the arteries in the head, neck, upper body, and arms. TAK specifically affects the aorta, the largest blood vessel in the body, and its branches. Therapies are available to improve the symptoms of GCA and TAK, but relapse often occurs, and better treatments are needed. Abatacept is a drug that interacts with certain cells in the body that are involved with GCA and TAK. This study will evaluate the effectiveness of abatacept in treating GCA and TAK and preventing disease relapse.

NCT ID: NCT00430807 Completed - Clinical trials for Giant Cell Arteritis

Hydroxychloroquine in Giant Cell Arteritis

Start date: January 2002
Phase: Phase 3
Study type: Interventional

Cortico-dependence is frequent in giant cell arteritis patients, and no drugs has proved its ability to prevent corticodependence. Hydrocychloroquine is a well tolerated immunomodulatory drug that may have a corticosteroid sparing potential according to immuno-pharmacological and clinical data. We have designed a multcentric double blind versus placebo randomized controled trial to assess the corticosteroid sparing effect of hydroxychloroquine in non complicated giant cell arteritis.

NCT ID: NCT00315497 Completed - Temporal Arteritis Clinical Trials

Determining Disease Activity Biomarkers in Individuals With Giant Cell Arteritis

Start date: April 2006
Phase:
Study type: Observational

Giant cell arteritis (GCA), also known as temporal arteritis, is a disease that usually only occurs in older adults. GCA causes inflammation of blood vessels, or vasculitis. In order to properly treat this disease, it is critical that the level of disease activity can be determined over the course of the disease. The purpose of this study is to determine new biological markers, or biomarkers, that may be used to assess the severity of disease in people with GCA.

NCT ID: NCT00315471 Completed - Clinical trials for Takayasu's Arteritis

Determining Disease Activity Biomarkers in Individuals With Takayasu's Arteritis

Start date: April 2006
Phase:
Study type: Observational

Takayasu's arteritis is a rare disorder that causes swelling and damage to the large arteries in the body, such as the aorta. In order to ensure proper treatment, measuring disease activity is critical. The purpose of this study is to establish new biological markers (biomarkers) to assess the severity of disease in people with Takayasu's arteritis.

NCT ID: NCT00305539 Completed - Clinical trials for Giant Cell Arteritis

HECTHOR: Humira to Spare Steroids in Giant Cell Arteritis

Start date: May 2006
Phase: Phase 3
Study type: Interventional

Hypothesis: In giant cell arteritis (GCA), a short initial treatment with anti-TNF may allow a faster decrease of steroids dosage and therefore avoid some of the adverse events of steroids.

NCT ID: NCT00221715 Completed - Diabetes Clinical Trials

Comparison of Two Lower Limb Bypass Types : Prosthesis Versus Autologous Vein

REVA
Start date: July 2002
Phase: N/A
Study type: Interventional

When medical treatments fail, critical ischemia of the lower limb often leads to surgery, i.e. above knee femoro popliteal bypass. This bypass can be performed either with DACRON or PTFE prosthesis or with the autologous saphenous vein. Both technics are used but they have not been compared regarding bypass permeability and limb salvage. Thus, this study will compare the permeability rate of above knee femoro popliteal surgery whether performed with autologous vein versus prosthesis

NCT ID: NCT00004686 Completed - Clinical trials for Giant Cell Arteritis

Phase II Randomized Study of Glucocorticoids With or Without Methotrexate for Treatment of Giant Cell Arteritis

Start date: February 1994
Phase: Phase 2
Study type: Interventional

OBJECTIVES: I. Compare the long term outcomes in patients with giant cell arteritis after glucocorticoid treatment with or without methotrexate. II. Compare remission relapse rates in these patients after glucocorticoid therapy with or without methotrexate. III. Determine whether adjunctive use of methotrexate lowers cumulative dose and duration of glucocorticoid therapy and whether there is less treatment related morbidity and mortality. IV. Demonstrate the feasibility of long term, double blind, placebo controlled, randomized, multicenter trials for treatment of systemic vasculitides.